In this study, the novel ADC MORAb-202, which comprises an anti-FOLR1 antibody and farletuzumab-linked eribulin, demonstrated a significant inhibition of proliferation in the FOLR1-expressing breast cancer cell lines. Here, FOLR1 is linked to breast carcinoma.